Annals of Surgical Oncology

, 14:306 | Cite as

Lymphadenectomy for Adenocarcinoma of the Gastroesophageal Junction (GEJ): Impact of Adequate Staging on Outcome

  • Andrew P. Barbour
  • Nabil P. Rizk
  • Mithat Gonen
  • Laura Tang
  • Manjit S. Bains
  • Valerie W. Rusch
  • Daniel G. Coit
  • Murray F. Brennan



Adequate staging of gastric cancer requires examination of at least 15 lymph nodes. Most resected patients are inadequately staged potentially confounding the interpretation of clinical data. The aim of this study was to determine whether adequate staging revealed different prognostic factors or improved survival compared with patients with <15 nodes examined after R0 resection for GEJ cancer.


A prospectively maintained database identified 366 patients with Siewert types II and III adenocarcinoma of the GEJ who underwent R0 resection without neoadjuvant therapy at a single institution. Patients were grouped into adequately (≥15 nodes examined) or inadequately staged (<15 nodes examined). Median follow up was 51 months.


From 1985 through 2003, 250/366 (68%) patients were adequately staged and 116/366 (32%) were inadequately staged. There was no difference in operative mortality between adequately staged (5.2%) and inadequately staged patients (4.3%, P = NS). Adequately staged patients had more positive lymph nodes (median 2) compared with inadequately staged patients (median 1, P < 0.01). Multivariable analysis of adequately staged patients found the number of positive lymph nodes, T stage, and lymphovascular invasion to be independent prognostic factors for overall survival (OS). For inadequately staged patients only the number of positive lymph nodes and T stage were independent prognostic factors. Adequate staging was an independent prognostic factor for patients with advanced (T ≥ 2 Nany) tumors. For T1 tumors adequate staging was not associated with improved survival.


Patients with GEJ cancer should undergo adequate lymphadenectomy to permit examination of ≥15 lymph nodes allowing the accurate identification of prognostic variables. Removal of ≥15 lymph nodes is associated with more accurate survival estimates for patients with advanced disease.


Gastroesophageal junction Adenocarcinoma Staging Prognostic factors Lymphadenectomy 



The authors thank Marianne Beninati for her assistance and meticulous data acquisition.


  1. 1.
    Kelsen DP, Ginsberg R, Pajak TF, et al. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med 1998; 339:1979–84PubMedCrossRefGoogle Scholar
  2. 2.
    Medical Research Council Oesophageal Cancer Working Group. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet 2002; 359:1727–33CrossRefGoogle Scholar
  3. 3.
    Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001; 345:725–30PubMedCrossRefGoogle Scholar
  4. 4.
    Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy in operable gastric and lower oesophageal cancer: final results of a randomised, controlled trial (the MAGIC trial, ISRCTN 93793971). J. Clin. Oncol. 2005; 23(16S):308sGoogle Scholar
  5. 5.
    Walsh TN, Noonan N, Hollywood D, et al. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 1996; 335:462–7PubMedCrossRefGoogle Scholar
  6. 6.
    Hundahl SA, Macdonald JS, Benedetti J, et al. Surgical treatment variation in a prospective, randomized trial of chemoradiotherapy in gastric cancer: the effect of undertreatment. Ann Surg Oncol 2002; 9:278–86PubMedCrossRefGoogle Scholar
  7. 7.
    Siewert JR, Feith M, Werner M, et al. Adenocarcinoma of the esophagogastric junction: results of surgical therapy based on anatomical/topographic classification in 1,002 consecutive patients. Ann Surg 2000; 232:353–61CrossRefGoogle Scholar
  8. 8.
    Bonenkamp JJ, Hermans J, Sasako M, et al. Extended lymph-node dissection for gastric cancer. N Engl J Med 1999; 340:908–14PubMedCrossRefGoogle Scholar
  9. 9.
    Cuschieri A, Weeden S, Fielding J, et al. Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group. Br J Cancer 1999; 79:1522–30PubMedCrossRefGoogle Scholar
  10. 10.
    Roviello F, Marrelli D, Morgagni P, et al. Survival benefit of extended D2 lymphadenectomy in gastric cancer with involvement of second level lymph nodes: a longitudinal multicenter study. Ann Surg Oncol 2002; 9:894–900PubMedCrossRefGoogle Scholar
  11. 11.
    Siewert JR, Bottcher K, Stein HJ, et al. Relevant prognostic factors in gastric cancer: ten-year results of the German Gastric Cancer Study. Ann Surg 1998; 228:449–61PubMedCrossRefGoogle Scholar
  12. 12.
    Hulscher JB, van Sandick JW, Offerhaus GJ, et al. Prospective analysis of the diagnostic yield of extended en bloc resection for adenocarcinoma of the oesophagus or gastric cardia. Br J Surg 2001; 88:715–9PubMedCrossRefGoogle Scholar
  13. 13.
    Lerut T, Coosemans W, Decker G, et al. Extended surgery for cancer of the esophagus and gastroesophageal junction. J Surg Res 2004; 117:58–63PubMedCrossRefGoogle Scholar
  14. 14.
    Hagen JA, DeMeester SR, Peters JH, et al. Curative resection for esophageal adenocarcinoma: analysis of 100 en bloc esophagectomies. Ann Surg 2001; 234:520–30PubMedCrossRefGoogle Scholar
  15. 15.
    D’Journo XB, Doddoli C, Michelet P, et al. Transthoracic esophagectomy for adenocarcinoma of the oesophagus: standard versus extended two-field mediastinal lymphadenectomy? Eur J Cardiothorac Surg 2005; 27:697–704PubMedCrossRefGoogle Scholar
  16. 16.
    van de Ven C, De Leyn P, Coosemans W, et al. Three-field lymphadenectomy and pattern of lymph node spread in T3 adenocarcinoma of the distal esophagus and the gastro-esophageal junction. Eur J Cardiothorac Surg 1999; 15:769–73PubMedCrossRefGoogle Scholar
  17. 17.
    Dresner SM, Lamb PJ, Bennett MK, et al. The pattern of metastatic lymph node dissemination from adenocarcinoma of the esophagogastric junction. Surgery 2001; 129:103–9PubMedCrossRefGoogle Scholar
  18. 18.
    Hulscher JB, van Sandick JW, de Boer AG, et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med 2002; 347:1662–9PubMedCrossRefGoogle Scholar
  19. 19.
    Chu KM, Law SY, Fok M, et al. A prospective randomized comparison of transhiatal and transthoracic resection for lower-third esophageal carcinoma. Am J Surg 1997; 174:320–4PubMedCrossRefGoogle Scholar
  20. 20.
    Lerut T, Nafteux P, Moons J, et al. Three-field lymphadenectomy for carcinoma of the esophagus and gastroesophageal junction in 174 R0 resections: impact on staging, disease-free survival, and outcome: a plea for adaptation of TNM classification in upper-half esophageal carcinoma. Ann Surg 2004; 240:962–72PubMedCrossRefGoogle Scholar
  21. 21.
    de Manzoni G, Pedrazzani C, Verlato G, et al. Comparison of old and new TNM systems for nodal staging in adenocarcinoma of the gastro-oesophageal junction. Br J Surg 2004; 91:296–303PubMedCrossRefGoogle Scholar
  22. 22.
    Greene FL, Page DL, FLeming ID, et al. (2002) AJCC cancer staging handbook, 6th edn. New York: Springer-Verlag.Google Scholar
  23. 23.
    Hundahl SA, Phillips JL, Menck HR. The National Cancer Data Base Report on poor survival of U.S. gastric carcinoma patients treated with gastrectomy: fifth edition American Joint Committee on Cancer staging, proximal disease, and the “different disease” hypothesis. Cancer 2000; 88:921–32PubMedCrossRefGoogle Scholar
  24. 24.
    Siewert JR, Stein HJ. Classification of adenocarcinoma of the oesophagogastric junction. Br J Surg 1998; 85:1457–9PubMedCrossRefGoogle Scholar
  25. 25.
    Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma, 2nd English edition. Gastric Cancer 1998; 1:10–24PubMedCrossRefGoogle Scholar
  26. 26.
    Miller R, Siegmund D. Maximally selected chi-square statistics. Biometrics 1982; 38:1011–16CrossRefGoogle Scholar
  27. 27.
    Mariette C, Castel B, Toursel H, et al. Surgical management of and long-term survival after adenocarcinoma of the cardia. Br J Surg 2002; 89:1156–63PubMedCrossRefGoogle Scholar
  28. 28.
    Di Martino N, Izzo G, Cosenza A, et al. Surgical therapy of adenocarcinoma of the esophagogastric junction: analysis of prognostic factors. Hepatogastroenterology 2005; 52:1110–5PubMedGoogle Scholar
  29. 29.
    Korst RJ, Rusch VW, Venkatraman E, et al. Proposed revision of the staging classification for esophageal cancer. J Thorac Cardiovasc Surg 1998; 115:660–9PubMedCrossRefGoogle Scholar
  30. 30.
    Kattan MW, Karpeh MS, Mazumdar M, et al. Postoperative nomogram for disease-specific survival after an R0 resection for gastric carcinoma. J Clin Oncol 2003; 21:3647–50PubMedCrossRefGoogle Scholar
  31. 31.
    Novotny AR, Schuhmacher C, Busch R, et al. Predicting individual survival after gastric cancer resection: validation of a U.S.-derived nomogram at a single high-volume center in Europe. Ann Surg 2006; 243:74–81PubMedCrossRefGoogle Scholar
  32. 32.
    Langley SM, Alexiou C, Bailey DH, et al. The influence of perioperative blood transfusion on survival after esophageal resection for carcinoma. Ann Thorac Surg 2002; 73:1704–9PubMedCrossRefGoogle Scholar
  33. 33.
    Adachi Y, Yasuda K, Inomata M, et al. Pathology and prognosis of gastric carcinoma: well versus poorly differentiated type. Cancer 2000; 89:1418–24PubMedCrossRefGoogle Scholar
  34. 34.
    Takahashi I, Matsusaka T, Onohara T, et al. Clinicopathological features of long-term survivors of scirrhous gastric cancer. Hepatogastroenterology 2000; 47:1485–8PubMedGoogle Scholar
  35. 35.
    Zafirellis K, Dolan K, Fountoulakis A, et al. Multivariate analysis of clinical, operative and pathologic features of esophageal cancer: who needs adjuvant therapy? Dis Esophagus 2002; 15:155–9PubMedCrossRefGoogle Scholar
  36. 36.
    Gabbert HE, Meier S, Gerharz CD, et al. Incidence and prognostic significance of vascular invasion in 529 gastric-cancer patients. Int J Cancer 1991; 49:203–7PubMedCrossRefGoogle Scholar
  37. 37.
    Kooby DA, Suriawinata A, Klimstra DS, et al. Biologic predictors of survival in node-negative gastric cancer. Ann Surg 2003; 237:828–35PubMedCrossRefGoogle Scholar
  38. 38.
    von Rahden BH, Stein HJ, Feith M, et al. Lymphatic vessel invasion as a prognostic factor in patients with primary resected adenocarcinomas of the esophagogastric junction. J Clin Oncol 2005; 23:874–9CrossRefGoogle Scholar
  39. 39.
    Roukos DH. Extended (D2) lymph node dissection for gastric cancer: do patients benefit? Ann Surg Oncol 2000; 7:253–5PubMedCrossRefGoogle Scholar
  40. 40.
    Sano T, Sasako M, Yamamoto S, et al. Gastric cancer surgery: morbidity and mortality results from a prospective randomized controlled trial comparing D2 and extended para-aortic lymphadenectomy—Japan Clinical Oncology Group study 9501. J Clin Oncol 2004; 22:2767–73PubMedCrossRefGoogle Scholar
  41. 41.
    Karpeh MS, Leon L, Klimstra D, et al. Lymph node staging in gastric cancer: is location more important than number? An analysis of 1,038 patients. Ann Surg 2000; 232:362–71PubMedCrossRefGoogle Scholar
  42. 42.
    Bunt AM, Hermans J, van de Velde CJ, Sasako M, Hoefsloot FA, Fleuren G, Bruijn JA. Lymph node retrieval in a randomized trial on western-type versus Japanese-type surgery in gastric cancer. J Clin Oncol 1996; 14:2289–94PubMedGoogle Scholar
  43. 43.
    Candela FC, Urmacher C, Brennan MF. Comparison of the conventional method of lymph node staging with a comprehensive fat-clearing method for gastric adenocarcinoma. Cancer 1990; 66:1828–32PubMedCrossRefGoogle Scholar
  44. 44.
    Hochwald SN, Brennan MF, Klimstra DS, et al. Is lymphadenectomy necessary for early gastric cancer? Ann Surg Oncol 1999; 6:664–70PubMedCrossRefGoogle Scholar
  45. 45.
    Stein HJ, Feith M, Bruecher BL, et al. Early esophageal cancer: pattern of lymphatic spread and prognostic factors for long-term survival after surgical resection. Ann Surg 2005; 242:566–73PubMedGoogle Scholar

Copyright information

© Society of Surgical Oncology 2006

Authors and Affiliations

  • Andrew P. Barbour
    • 1
  • Nabil P. Rizk
    • 1
  • Mithat Gonen
    • 2
  • Laura Tang
    • 3
  • Manjit S. Bains
    • 1
  • Valerie W. Rusch
    • 1
  • Daniel G. Coit
    • 1
  • Murray F. Brennan
    • 1
  1. 1.Department of SurgeryMemorial Sloan-Kettering Cancer CenterNew YorkUSA
  2. 2.Department of Epidemiology-BiostatisticsMemorial Sloan-Kettering Cancer CenterNew YorkUSA
  3. 3.Department of PathologyMemorial Sloan-Kettering Cancer CenterNew YorkUSA

Personalised recommendations